Search results: (10000)
News Long-term Efficacy and Safety of Mavacamten in the Treatment of Obstructive HCM
Interim results of the MAVA-LTE study provide the latest data on the long-term safety and efficacy of symptomatic treatment with mavacamten for obstructive hypertrophic cardiomyopathy (oHCM), with the longest follow-up period nearly 2.5 years. For clinical practice, the long-term reduction of left ventricular outflow tract (LVOT) obstruction and good tolerability of the treatment are particularly favorable.
News Mavacamten in the Treatment of HCM in Patients Referred for Septal Reduction
Extended 56-week follow-up of patients with hypertrophic cardiomyopathy (HCM) resistant to current pharmacotherapy in the VALOR-HCM study confirmed the lasting benefit of mavacamten – the first representative of a new class of selective reversible cardiac myosin inhibitors – as a new pharmacological treatment option reducing the need for invasive procedures.
News MUDr. Jana Zárubová: Experiences with buccal midazolam in real practice are positive and we can significantly improve patients' quality of life
Recently, it has emerged as an alternative to traditionally rectally administered diazepam for stopping prolonged convulsive seizures in patients with epilepsy. What can buccal midazolam offer them and how has it proven itself in real practice? MUDr. Jana Zárubová from the Neurological Clinic of the 2nd Faculty of Medicine, Charles University and Motol University Hospital in Prague describes.
News IEC 2023: Key Challenges for Epilepsy Patients Include Status Epilepticus and Anxiety Management
Why is anxiety a significant issue for epilepsy patients? What do current insights say about the connection between epilepsy and anxiety? Can artificial intelligence be used to predict status epilepticus (SE)? And what is known about the development of late epilepsy following new SE? These and other topics were discussed in September 2023 in Dublin during the 35th International Epilepsy Congress (IEC 2023).
News Somapacitan administered once weekly in the treatment of children with growth hormone deficiency – current understanding
Somapacitan is a long-acting derivative of recombinant human growth hormone approved for the treatment of children and adults with growth hormone (GH) deficiency. Dr. Reiko Horikawa from Japan's National Center for Child Health and Development in Tokyo, during the 24th Pediatric Endocrinology Days held in Brno in January 2024, showed that it is a promising therapeutic option for pediatric patients from 3 years of age, thanks to its efficacy, safety, and potential to improve therapy adherence. However, careful long-term monitoring of the safety of long-acting growth hormone (LAGH) products is still necessary.
News Clinical Significance of Smaller Gaps Between Strengths of Levothyroxine Preparations in the Treatment of Hypothyroidism
Many levothyroxine preparations have relatively large intervals between doses (25 µg, 50 µg, and 75 µg), creating obstacles for some patients to achieve an optimal maintenance dose. The availability of tablets that allow for dosing in between these values facilitates precise and effective titration of levothyroxine doses, especially at the lower end of the spectrum.
News Lurasidone in a Patient with Paranoid Schizophrenia and Asperger's Syndrome – A Case Study
Lurasidone is an effective and very gentle antipsychotic which is establishing a prominent position in modern psychopharmacotherapy. Its unique receptor profile makes it a suitable choice for hyperprolactinemia induced by risperidone. A significant benefit of lurasidone is its favorable cardiometabolic profile. Switching from another antipsychotic to lurasidone can be performed on an outpatient basis. Most importantly, it is essential to highlight its effect on both positive and negative symptoms of schizophrenia, as demonstrated by the presented case study.
News Meta-analysis of the Effectiveness of Romosozumab in the Treatment of Postmenopausal Osteoporosis
Osteoporosis is a prevalent disease with unmet therapeutic needs. Whether the anti-sclerostin antibody romosozumab can offer an effective improvement in osteoporosis treatment outcomes in postmenopausal women was the central question addressed by the meta-analysis presented below.
News Scientists Decipher the Perception of Bitter Taste. How Will This Help in the Development of New Drugs?
Taste receptors are a known phenomenon, but how exactly does taste perception occur? Scientists from the University of North Carolina focused on bitter taste, as it often accompanies medications. They hope their research will allow the application of their findings, for example, in the development of treatments for obesity or diabetes mellitus (DM).
News Distribution and Localization of Specifically Modified Exosomes Can Improve the Treatment of Muscular Dystrophies
A research team from several Milanese universities, in a study published in Nature Nanotechnology, focused on developing a new method for muscular dystrophy therapy. Specifically modified exosomes were enriched with the protein annexin A1 and delivered into dystrophic muscle cells using ferromagnetic nanotubes guided by an external magnetic field. This triggered healing processes in damaged cells and tissues in a mouse model.
News One Step Closer to Understanding the Placebo Effect in Pain Treatment
Neuroscientists from the USA appear to have advanced our understanding of the placebo effect in pain relief. Their findings, recently published in Nature, open the possibility of influencing the described pain control pathway using drugs or neurostimulation.
News CASE STUDY: Surgical Procedure in an Adolescent Patient with Severe Hemophilia A on Emicizumab Prophylaxis
This case study is narrated by MUDr. Bohumír Blažek from the Clinic of Pediatric Medicine at LF OU and FN Ostrava. The patient is a 17-year-old boy with severe hemophilia A. Several months prior to the procedure under discussion, he was switched from prophylactic factor VIII administration to emicizumab prophylaxis. Subsequently, an extraction of all four molars was planned for orthodontic reasons. The case study describes the hematologist's approach to the procedure and the subsequent healing process.
News Effect of Administering Ferric Carboxymaltose on Quality of Life in Heart Failure Patients
The quality of life in patients with heart failure is significantly reduced. The concurrent occurrence of iron deficiency further exacerbates this situation. The AFFIRM-AHF study evaluated the impact of intravenous administration of ferric carboxymaltose on health-related quality of life (HRQoL) in patients with heart failure who also suffered from iron deficiency.
News Pharmacokinetic Comparison of Two EHL Products in Hemophilia A
According to a Canadian study published last year, certain pharmacokinetic differences were observed between two extended half-life factors.